Revenues up for Hologic in FY2015 Q4
Hologic announced its fourth-quarter financial results this week, including $702.8 million in revenue. That number is up more than 6 percent compared to 2014.
When taking account of the one-time benefit of amending the company’s license agreement with Roka Bioscience, all four of Hologic’s businesses—diagnostics, breast health, GYN surgical, and skeletal health—saw increases in revenue. Excluding that benefit, breast health, GYN surgical, and skeletal health still made significant gains.
“Hologic's strong fourth quarter financial results capped off an outstanding year in which our people and our products enabled us to exceed expectations across the board,” Steve MacMillan, Hologic chairman, president and CEO, said in a statement. “In the fourth quarter, revenue again increased at a double-digit rate on a constant currency basis excluding the one-time Roka benefit, while earnings per share grew even faster. And importantly, all four of our primary businesses grew in the United States and Internationally on a constant currency basis.”
The company’s net income, it announced, was down more than 10 percent in fourth quarter.
Research firm Zacks presently ranks the Massachusetts-based imaging company as a “hold.”
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.